The Use of Fetal Fibronectin to Predict Delivery Due to Abruptio Placenta
The Use of Fetal Fibronectin (fFN) in Predicting Preterm Delivery Due to Abruptio Placenta in Patients With Minor Maternal Trauma.
Sponsor: Winthrop University Hospital
Terminated
Quantitative assessment of fFN only able to be performed at one laboratory.
Other terminated trials from Winthrop University Hospital
Other Abruptio Placentae trials with similar outcome
A observational or N/A phase clinical study on Abruptio Placentae and Pregnancy Related, this trial is terminated or withdrawn. The trial is conducted by Winthrop University Hospital and has accumulated 10 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Nov 2020 — Jan 2021 [monthly]
Terminated
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated
-
May 2018 — Jun 2018 [monthly]
Terminated
-
Apr 2018 — May 2018 [monthly]
Terminated
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Terminated NA
-
Jan 2017 — Aug 2017 [monthly]
Terminated NA
First recorded
Oct 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Winthrop University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .